Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury
Sponsor: Rigshospitalet, Denmark
Summary
Cortical spreading depolarisations are pathological depolarisation waves that occur frequently after severe acute brain injury and has been associated with poor outcome. S-ketamine has been shown to inhibit cortical spreading depolarisations. The aim of the present study is to examine the efficacy and safety of using S-ketamine for treatment of patients with severe acute brain injury, as well as the feasibility of the trial design.
Official title: S-ketamine for Cortical Spreading Depolarisation in Patients With Severe Acute Brain Injury
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2023-09-15
Completion Date
2028-09-15
Last Updated
2024-06-26
Healthy Volunteers
No
Interventions
S-ketamine
S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.
Isotonic saline (placebo)
Isotonic saline has the same appearance as S-ketamine with both being clear liquids with no bubbles or other distinguishing features.
Locations (1)
Rigshospitalet
Copenhagen, Denmark